MICRO PLUS 5 CONCENTRATE LIQUID

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

MANGANESE (MANGANESE SULFATE); CHROMIUM (CHROMIC CHLORIDE); SELENIUM (SELENIOUS ACID); COPPER (CUPRIC SULFATE); ZINC (ZINC SULFATE)

Предлага се от:

SANDOZ CANADA INCORPORATED

АТС код:

B05XA31

INN (Международно Name):

ELECTROLYTES IN COMB WITH OTHER DRUGS

дозиране:

0.5MG; 10MCG; 60MCG; 1MG; 5MG

Лекарствена форма:

LIQUID

Композиция:

MANGANESE (MANGANESE SULFATE) 0.5MG; CHROMIUM (CHROMIC CHLORIDE) 10MCG; SELENIUM (SELENIOUS ACID) 60MCG; COPPER (CUPRIC SULFATE) 1MG; ZINC (ZINC SULFATE) 5MG

Начин на приложение:

INTRAVENOUS

Броя в опаковка:

10ML

Вид предписание :

Ethical

Терапевтична област:

REPLACEMENT PREPARATIONS

Каталог на резюме:

Active ingredient group (AIG) number: 0531376001; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2006-06-09

Данни за продукта

_MICRO +5 CONCENTRATE (5 Trace Elements Injection USP) _
_Page 1 of 18_
_ _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
MICRO +5 CONCENTRATE
5 Trace Elements Injection
Zinc, 5 mg/mL
Copper, 1 mg/mL
Manganese, 0.5 mg/mL
Chromium, 10 mcg/mL
Selenium, 60 mcg/mL
USP
Intravenous
Combination of Electrolytes
Sandoz Canada Inc.
110 Rue de Lauzon
Boucherville, (Québec), Canada
J4B 1K6
Date of Initial Authorization:
APR 25, 1994
Date of Revision:
December 16, 2021
Control No.:250303
_MICRO +5 CONCENTRATE (5 Trace Elements Injection USP) _
_Page 2 of 18_
RECENT MAJOR LABEL CHANGES
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and
Dosage Adjustment (Pediatrics)
12/2021
7 WARNINGS AND PRECAUTIONS, General
12/2021
TABLE OF CONTENTS
Sections of subsections that are not applicable at the time of
authorization are not listed.
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................. 4
1
INDICATIONS
....................................................................................................................
4
1.1
P
EDIATRICS
(
≤
18 YEARS OF AGE
)
.................................................................................
4
1.2
G
ERIATRICS
(≥
65 YEARS OF AGE
)
..................................................................................
4
2
CONTRAINDICATIONS
.....................................................................................................
4
4
DOSAGE AND ADMINISTRATION
....................................................................................
4
4.1
D
OSING
C
ONSIDERATIONS
...................................................................................................
4
4.2
R
ECOMMENDED
D
OSE AND
D
OSAGE
A
DJUSTMENT
............................................................... 5
4.3
R
ECONSTITUTION
................................................................................................................
6
4.4
A
DMINISTRATION
.............................................................................